Volume 1, Issue 24


Cover Image

Cover Figure:  Peripheral lymph nodes biopsied before and after desensitization with dual targeting.
See the article by Kwun et al.

WASHINGTON, November 14,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

In a Blood Advances Talk, Francesco Rodeghiero  discusses the interesting interaction between immune thrombocytopenia (ITP) and thrombosis. We hope you enjoy the talk.


It is well recognized that there are significant disparities in incidence and outcomes with a number of different malignancies. Darbinyan et al evaluate acute myeloid leukemia in patients of Hispanic ethnicity.


The management of patients with immune thrombocytopenia can be challenging and many patients relapse after first-line treatment. In a review, Neunert discusses the management of this disorder.


Obesity has been shown to have an impact in hematological malignancies such as multiple myeloma (MM). However, the role of obesity in monoclonal gammopathy of undetermined significance and progression to MM is controversial. Thordardottir et al , evaluated the population-based AGES Reykjavik study of patients in Iceland and found a surprising and interesting impact of obesity on these conditions.


Viral infections are common after allogeneic bone marrow transplantation, and these infections can be persistent and life-threatening. An attractive approach is to generate antiviral T cells for adoptive transfer. Withers and colleagues utilized third-party virus-specific T cells with very encouraging results with respect to long-term viral control.


Choosing among different treatment options can be a daunting task, as there are many variables of potential importance. Mansfield and colleagues explored this issue in a study of patients with chronic lymphocytic leukemia, with interesting and perhaps surprising results.


The use of allogeneic transplantation for induction of tolerance has been a long-standing goal in the field. The group led by Reisner and colleagues has explored the concept of T-cell-depleted megadose stem cell transplantation to avoid complications of graft-versus-host disease. However, this approach is limited in the setting of nonmyeloablative conditioning because of the risk of graft rejection. Aversa and colleagues used murine models to demonstrate that the combination of megadose transplantation and posttransplant cyclophosphamide results in durable engraftment. Proof-of-concept studies with several patients are also presented to demonstrate that this concept can be translated to the clinic. Further studies are clearly warranted.

Vaccination against cancer tumor antigens is an attractive concept, especially as new and more effective immune modulating drugs are developed. Ho et al explore the impact of a vaccination strategy with autologous myeloblasts and K562 cells expressing granulocyte-macrophage colony-stimulating factor, collectively known as GVAX.


Featured Visual Abstract

TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Patients with antiphospholipid syndrome are at risk for recurrent arterial thrombosis. The most effective way to manage these patients is controversial. The study from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking compared the use of anticoagulation, antiplatelet, and combined therapies in a retrospective analysis. The findings could have a major impact on the management of these patients.


Blood Advances is the open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.